Avalo Therapeutics News and Activities
Presence
Avalo Therapeutics is a biotechnology company that develops medicines for immune and inflammatory diseases. Its drug pipeline serves patients, healthcare providers, and partners focused on respiratory, inflammatory, and rare conditions.
Avalo Therapeutics products and services overview:
- Drug discovery
- Clinical development
- Immunology therapies
- Inflammation treatments
- Respiratory therapies
- Rare disease therapies
Revenue: ~$0 million
Employees: 25
Headquarters: Rockville, United States (USA)
Avalo Therapeutics is one of the...
Avalo Therapeutics is a company listed under the stock ticker AVTX (US).
Acquisition, funding and merger involving Avalo Therapeutics.
- Avalo Therapeutics has just announced a $375 Million fundraising (posted on May 6 2026).
Executives
View the org chart displaying its 29 main executives
Most searched biographies at Avalo Therapeutics
Popular executive movements at Avalo Therapeutics
- Ron Philip has joined the company as Director (posted on June 23 2026).
Create your alert
to follow the executive moves at Avalo Therapeutics.
Biotechnology
Avalo Therapeutics has 2,428 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Eli Lilly has announced the acquisition of AtaiBeckley (posted on July 17 2026).
- GSK has acquired Nuvalent (posted on July 17 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (posted on July 15 2026).
Popular contacts in Biotechnology
News
Press releases by Avalo Therapeutics
- Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer :: Avalo Therapeutics, Inc. (AVTX)
- Avalo Therapeutics to Present at Upcoming Investor Conferences :: Avalo Therapeutics, Inc. (AVTX)
- Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants :: Avalo Therapeutics, Inc. (AVTX)
- Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates :: Avalo Therapeutics, Inc. (AVTX)
- Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa :: Avalo Therapeutics, Inc. (AVTX)
- Avalo Announces Participation in September Investor Conferences :: Avalo Therapeutics, Inc. (AVTX)
- Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer :: Avalo Therapeutics, Inc. (AVTX)
- Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates :: Avalo Therapeutics, Inc. (AVTX)
- Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa :: Avalo Therapeutics, Inc. (AVTX)
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit :: Avalo Therapeutics, Inc. (AVTX)
- View more press releases Close
Social media about Avalo Therapeutics
- Avalo Therapeutics on Wikipedia, Google News & Yahoo Finance
- Avalo Therapeutics on LinkedIn, X (Twitter) & YouTube
